Insider Trading25 Jun 2026, 02:56 pm
Glenmark Pharma Closes Trading Window for Insider Trading
AI Summary
Glenmark Pharmaceuticals Ltd has announced the closure of its trading window for designated persons, key managerial personnel, identified employees, and connected persons. This prohibition on trading in the company's securities will commence from July 01, 2026, and will remain in effect until the declaration of the unaudited financial results for the first quarter ended June 30, 2026, plus forty-eight hours thereafter. The specific date for the board meeting to approve these results will be communicated separately. This measure is in compliance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal code of conduct.
Key Highlights
- Trading window closure effective July 01, 2026.
- Applies to designated persons and immediate relatives.
- Remains closed until after Q1 FY26 financial results announcement.
- Aims to prevent insider trading activities.
- Company will announce board meeting date for results soon.
Price Impact
More from GLENMARK